Literature DB >> 12848977

Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis.

J Ludovic Croxford1, Julie K Olson, Stephen D Miller.   

Abstract

The pathogenesis of multiple sclerosis (MS), a human demyelinating disease of the central nervous system (CNS), is currently unknown. It is widely thought that MS is an autoimmune disease which is supported by animal studies showing that myelin-specific CD4+ T cells can induce similar clinical disease in mice as observed in MS. However, the mechanism(s) of activation of these autoreactive CD4+ T cells are unknown. Although genetic susceptibility is important, other factors may be involved. Viral infections have long thought to be involved in the pathogenesis of MS although there exists little or no direct evidence implicating a role for a specific virus in MS pathogenesis. This review will discuss two models of virus-induced CNS autoimmunity, molecular mimicry and epitope spreading. These two mechanisms of activation of autoreactive T cells are presented in the context of MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12848977     DOI: 10.1016/s1568-9972(02)00080-0

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  32 in total

1.  Initiation and exacerbation of autoimmune demyelination of the central nervous system via virus-induced molecular mimicry: implications for the pathogenesis of multiple sclerosis.

Authors:  J Ludovic Croxford; Julie K Olson; Holly A Anger; Stephen D Miller
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 2.  CD46 plasticity and its inflammatory bias in multiple sclerosis.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2011-01-26       Impact factor: 4.291

Review 3.  Transgenic mouse models of multiple sclerosis.

Authors:  Tanja Scheikl; Béatrice Pignolet; Lennart T Mars; Roland S Liblau
Journal:  Cell Mol Life Sci       Date:  2010-08-17       Impact factor: 9.261

4.  Generation of a protective T-cell response following coronavirus infection of the central nervous system is not dependent on IL-12/23 signaling.

Authors:  Katherine S Held; William G Glass; Yevgeniya I Orlovsky; Kimberly A Shamberger; Ted D Petley; Patrick J Branigan; Jill M Carton; Heena S Beck; Mark R Cunningham; Jacqueline M Benson; Thomas E Lane
Journal:  Viral Immunol       Date:  2008-06       Impact factor: 2.257

5.  Autoantibodies in patients with chronic obstructive pulmonary disease.

Authors:  Carol A Feghali-Bostwick; Aneal S Gadgil; Leo E Otterbein; Joseph M Pilewski; Michael W Stoner; Eva Csizmadia; Yingze Zhang; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

Review 6.  Astrocytes in multiple sclerosis: a product of their environment.

Authors:  A Nair; T J Frederick; S D Miller
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

7.  Depletion of Olig2 in oligodendrocyte progenitor cells infected by Theiler's murine encephalomyelitis virus.

Authors:  Bayleigh Benner; Anthony J Martorell; Padmanabhan Mahadevan; Fadi J Najm; Paul J Tesar; Eric C Freundt
Journal:  J Neurovirol       Date:  2015-12-02       Impact factor: 2.643

8.  The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.

Authors:  Francesca Gilli; Libin Li; Andrew R Pachner
Journal:  J Neurovirol       Date:  2015-08-11       Impact factor: 2.643

Review 9.  Modeling multiple sclerosis in laboratory animals.

Authors:  Bettina Schreiner; Frank L Heppner; Burkhard Becher
Journal:  Semin Immunopathol       Date:  2009-10-03       Impact factor: 9.623

Review 10.  Virus infection, antiviral immunity, and autoimmunity.

Authors:  Daniel R Getts; Emily M L Chastain; Rachael L Terry; Stephen D Miller
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.